Abstract: The present invention relates to a phytocomplex or natural concentrate rich in polyphenolic compounds, such as hydroxytyrosol and 3,4-DHPA-EDA, derived from the vegetation waters of oil-bearing olives or from olive pomace resulting from the olive milling process for use in the treatment and prevention of angiogenesis and inflammation. In particular, the angiogenesis and inflammation to which reference is made is pathologic angiogenesis and inflammation, for example that which sustains the development and spread of a tumor or angiogenesis and inflammation tied to non-tumor pathologies. The present invention further relates to a beverage comprising the polyphenol concentrate and the use thereof in the treatment and prevention of angiogenesis and inflammation.

Abstract: Compositions, dietary supplement compositions, and topical compositions including activated fatty acids and methods for using activated fatty acids to treat a variety of diseases.

Abstract: A topically admimstrable vasodilator formulation comprises arginine and/or one or more derivatives thereof, black pepper extract and/or one or more components or derivatives thereof; and peppermint extract and/or one or more components or derivatives thereof. The formulation may further comprise rosemary oil, a penetration enhancers, an ecdysteroid and/or one or more other agents that enhance the vasodilator activity of the formulation. The valodilator formulation may be suitable for treating or preventing a disease, disorder or condition associated with a decrease and/or impairment of blood flow in a subject by topically administration to the subject.

Abstract: The invention belongs to the field of medicine, involving new uses of Paliurus ramosissimus (Lour) Poir. and its extract, in particular the use of Paliurus ramosissimus (Lour) Poir. and its extract in preparation of drugs with anti-fibrotic, anti-fungal, and anti-tumor activities, for the treatment of oral and digestive tract inflammation or (and) ulcer-related diseases, or with bi-directional immunomodulatory effects.

Abstract: Provided are compositions and processes of treating or preventing one or more conditions related to a protein involved in circadian rhythm. A composition includes an extract of rosemary, an extract of hemerocallis fulva, active portion or component thereof, or combinations thereof, optionally provided as a component of a dietary supplement. The presence of one or more active ingredients in the extracts optionally administered at a targeted administration time alters the expression of one or more genes or proteins involved in circadian rhythm, illustratively CLOCK, BMAL1, FBXL3, FBXL21, or SIRT1.

Abstract: A method for the management of cancer and treatment of cancer comorbidities, including but not limited to cancer-related fatigue, cachexia, anorexia, pain, anemia, asthenia, depression, muscle weakness, nausea, vomiting, skin, and skin appendages adverse reactions; the method including the administration by the conventional and non-conventional oral, topical, parenteral routes and intra-tumoral injection, or in combination thereof, or the administration as adjuvant potentiator in other therapies using the forenamed routes, of a composition containing as active ingredient an extract of Allium species, which contains querceting, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.

Abstract: A composition for enhanced bioavailability of curcumin, and methods of making and using as a health supplement. The composition includes a curcuminoid mixture, essential oil of turmeric, and water extract of turmeric polysaccharides. The composition is derived from turmeric rhizomes and provides bioavailability benefits in a subject in need thereof.

Abstract: The disclosure provides methods of preventing, treating, or ameliorating LV remodeling in a mammalian subject. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide such as D-Arg-2,6-Dmt-Lys-Phe-NH2.

Abstract: The present invention relates to the field of virology. More specifically, the present invention provides compositions and methods useful for diagnosing and treating human cytomegalovirus. In one embodiment, a method for identifying a subject as susceptible to or likely to develop a human cytomegalovirus infection comprises the steps of (a) obtaining a biological sample from the subject; (b) performing an assay on the sample obtained from the subject to identify a mutation in NOD1 and/or NOD2; and (c) identifying the subject as susceptible to likely to develop human cytomegalovirus infection if the NOD1 and/or NOD2 mutation is identified.

Abstract: The present invention provides phosphorylcholine conjugates and pharmaceutical compositions comprising same for the prevention or treatment of autoimmune diseases. In particular, the conjugates of the present invention are effective in treating autoimmune diseases associated with pathological inflammation.

Abstract: The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.

Abstract: The present invention relates to peptides for inhibiting angiogenesis. The present invention also relates to methods of inhibiting angiogenesis and methods of treating disorders associated with VEGF-induced vascular permeability using the peptides of the invention.

Abstract: Described herein are materials and methods of treating dry eye disease in a subject.

Abstract: Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.

Abstract: Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.

Abstract: The invention relates to a method for enhancing wound healing in a subject in need thereof, comprising administering to the subject a composition comprising fibronectin type III domain-containing protein 5 (FNDC5) or its cleaved fragment irisin in an amount effective to enhance wound healing

Abstract: The disclosure provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit VLA-4 interaction with VEGFR2, thereby preventing tumor cell growth and tissue invasion.

Abstract: Disclosed are methods of treating chronic nervous system diseases or injuries, e.g., chronic spinal cord injury, using Nogo receptor antagonists, including Nogo receptor-1 (NgR1) polypeptides, Nogo receptor-1 antibodies and antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, and polynucleotides. Also disclosed are methods of noninvasively monitoring axonal growth during and after treatment with an axonal growth promoting agent.

Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.

Abstract: The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use.

Abstract: Polypeptides and agents that bind a TNF receptor superfamily protein are disclosed, particularly agents that specifically bind GITR, OX40, or CD40. The polypeptides or agents may include fusion polypeptides, particularly polypeptides comprising GITRL, OX40L, or CD40L and/or bispecific agents. Also disclosed are methods of using the polypeptides or agents for inducing and/or enhancing the immune response, as well as methods for the treatment of diseases such as cancer.

Abstract: Compositions comprising one or more cytokines and methods for their use in inhibiting and/or alleviating effects of radiation therapy and/or chemotherapy and/or acute radiation syndrome in a subject in need thereof are provided.

Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.

Abstract: The instant disclosure relates to methods useful for the treatment or prevention of progressive growth failure in a subject in need thereof. The method may include the step of administering a PAPPA2 gene product to the subject. Also disclosed is the identification of a novel gene mutation that may be used as a marker to identify subjects particularly suited for such treatment. Compositions containing a therapeutically effective amount of PAPPA2 protein and a pharmaceutically acceptable carrier are also disclosed.

Abstract: Methods are disclosed for treating post traumatic stress disorder (PTSD) in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A.

Abstract: This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.

Abstract: The present invention relates to, inter alia, safe and effective doses of a beta-lactamase for, e.g. microbiome protection.

Abstract: Methods of delivering viral vectors, particularly recombinant adeno-associated virus (rAAV) virions, to the central nervous system (CNS) using convection enhanced delivery (CED) are provided. The rAAV virions include a nucleic acid sequence encoding a therapeutic polypeptide. The methods can be used for treating CNS disorders such as for treating Parkinson's Disease.

Abstract: The present invention concerns a hexapeptide and its medical and/or diagnosis uses, in particular for the diagnosis and/or treatment of cancer.

Abstract: The disclosure includes compositions and methods for the production of an immune response against porcine reproductive and respiratory syndrome (PRRS) virus, or PRRSV. The disclosure is based in part on the use of two or more peptide domains, each with a different sequence, from the PRRSV GP5 protein ectodomain. Compositions and methods comprising polypeptides containing the two or more domains, or nucleic acids encoding them, are described.

Abstract: The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.

Abstract: This invention relates to methods of using a Listeria vaccine vector to induce a Th1 immune response in subjects having persistent Th2 immune response profiles.

Abstract: The present invention is directed to an effective HIV vaccine will most likely require the induction of strong T-cell responses, broadly neutralizing antibodies (bNAbs), and the elicitation of antibody-dependent cellular cytotoxicity (ADCC). Previously, we demonstrated the induction of strong HIV/SIV cellular immune responses in macaques and humans using synthetic consensus DNA immunogens delivered via adaptive electroporation (EP). However, the ability of this improved DNA approach to prime for relevant antibody responses has not been previously studied. Here, we investigate the immunogenicity of consensus DNA constructs encoding gp140 sequences from HIV-1 subtypes A, B, C and D in a DNA prime protein boost vaccine regimen. Mice and Guinea pigs were primed with single and multi-clade DNA via EP and boosted with recombinant gp120 protein. Sera were analyzed for gp120 binding and induction of neutralizing antibody activity.

Abstract: The instant invention provides methods for treatment or prevention of S equi and/or EHV in horses, the methods comprising administered to the horses in need thereof a com position comprising parapoxvirus ovis.

Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are particularly suitable for delivering nucleic acid molecules (such as an RNA molecule encoding an antigen) to cells and formulating nucleic acid-based vaccines.

Abstract: Disclosed is the use of lipopeptides and lipoproteins as mucosal adjuvants for various vaccinations via mucous membranes, particularly intranasally. Said lipopeptides represent peptides or proteins substituted with 2,3-diacyloxy(2R)-propyl at the amino-terminal cystein of a peptide or protein, preferably S-(2,3-bis-palmitoyloxy-(2R)-propyl)cysteinyl peptides derived from mycoplasmas. Said peptides are highly effective even in small doses, produce good immunization results, and increase the IgA level, among others.

Abstract: There is provided an immunopotentiator comprising, as an active ingredient, a modified ?-glucan which ?-glucan and poly(hydroxy acid) are covalently bonded. The immunopotentiator can potently enhance the immunopotentiating effect of ?-glucan.

Abstract: A composition includes at least one mineral oil, a surfactant having a hydrophilic property characterised by an HLB value equal to 12 and a divalent inorganic salt intended to be used as an adjuvant in a vaccine composition for the in ovo vaccination of avian species wherein the composition is an oil-in-water emulsion or microemulsion.

Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.

Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.

Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.

Abstract: One or more techniques and/or products are disclosed using a process for preparing metallic nanoparticles. Resulting nanoparticles may comprise a gold-silver-gold core-shell-shell nanoparticles. Such nanoparticles can be formed by forming a gold core, providing certain materials to form a silver shell, and providing certain materials to form a gold shell. The metallic nanoparticles may be used in molecular sensing, catalysis, photothermal therapy, and other biologically-relevant technologies.

Abstract: A hydrogel-lightguide based sensory system susceptible to a stimulus signal produced by ambient and stimulating sensory cells embedded in a hydrogel body of the system. Sensory cells generate an optical signal (in response to a user-defined triggering with excitation light or, alternatively, due to bioluminescence) the properties of which, determined based on detection of such signal with an optical detector device, provide characterization of the stimulus and information required for user-defined activation of emitter cells encapsulated in the hydrogel. When activated, emitter cells generate matter and/or light directed to interact with the ambient.

Abstract: The present invention provides optical agents comprising optically functional cross linked supramolecular structures and assemblies useful for tandem optical imaging and therapy. Supramolecular structures and assemblies of the present invention include optically functional shell-cross linked micelles wherein optical functionality is achieved via incorporation of one or more linking groups that include one or more photoactive moieties. The present invention further includes imaging and therapeutic methods using one or more optical agents of the present invention including optically functional shell cross-linked micelles having an associated therapeutic agent.

Abstract: Research should be undertaken on different causes and at different ages for Attention Deficit/Hyperactivity Disorder and Obsessive Compulsive Disorder. The causes may be chronic pain, addictions, and traumas rather than genetic.

Abstract: Disclosed is a transdermal absorptive liquid preparation in which a medicament or a salt thereof is colloidally dispersed in propylene glycol or a propylene glycol-containing solvent, whose transdermal permeability of the medicament is excellent, problem of skin irritation is reduced. This transdermal absorptive liquid formulation has a mode of particle diameter at around 100 nm, and an average particle size of 50 to 500 nm. This transdermal absorptive liquid formulation makes marked improvement in the transdermal permeability by further containing an absorption promoter such as triethanolamine.

Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).

Abstract: The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

Abstract: A method for stabilising a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa.

Abstract: A flavor improver for a polyunsaturated fatty acid-containing fat or oil, containing a basic peptide; and a polyunsaturated fatty acid-containing fat or oil composition, containing a fat or oil containing a polyunsaturated fatty acid having 18 or more carbon atoms and two more double bonds, a basic amino acid and/or a basic peptide, and an emulsifying agent. The flavor improver for a polyunsaturated fatty acid-containing fat or oil and the polyunsaturated fatty acid-containing fat or oil composition of the present invention can suppress the generation of unpleasant taste and flavor from the polyunsaturated fatty acid over a long time period.